- Conditions
- Haemophilic Pseudotumour
- Interventions
- Emicizumab
- Drug
- Lead sponsor
- Indiana Hemophilia &Thrombosis Center, Inc.
- Other
- Eligibility
- Not listed
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 113
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hemophilia B
- Interventions
- AskBio009
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2030
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 11 more
- Conditions
- Hemophilia B with Inhibitor, Hemophilia B
- Interventions
- SerpinPC
- Drug
- Lead sponsor
- ApcinteX Ltd
- Industry
- Eligibility
- 12 Years to 65 Years · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Tampa, Florida • Greenville, North Carolina
- Conditions
- Hemophilia
- Interventions
- Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013, Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013
- Biological
- Lead sponsor
- American Thrombosis and Hemostasis Network
- Network
- Eligibility
- Not listed
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 27
- States / cities
- San Diego, California • Aurora, Colorado • New Haven, Connecticut + 23 more
- Conditions
- Hemophilia B
- Interventions
- SPK-9001
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 9
- States / cities
- Sacramento, California • Jackson, Mississippi • Madison, Mississippi + 2 more
- Conditions
- Hemophilia B
- Interventions
- rFIX
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2005
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Aurora, Colorado • Detroit, Michigan + 4 more
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- Recombinant Factor VIIa BI (rFVIIa BI)
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 12 Years to 65 Years · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Gene Therapy, Hemophilia B
- Interventions
- Interview
- Behavioral
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 150 participants
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- PF-06741086
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years to 74 Years · Male only
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Iowa City, Iowa • New Hyde Park, New York + 1 more
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- fitusiran, Bypassing agents
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 9 more
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- fitusiran, factor concentrates
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Gainesville, Florida • Tampa, Florida + 5 more
- Conditions
- Hemophilia B
- Interventions
- AAV5-hFIXco-Padua, Factor IX (FIX)
- Genetic · Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more
- Conditions
- Hemophilia B
- Interventions
- SB-FIX
- Biological
- Lead sponsor
- Sangamo Therapeutics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Significant Bleeding Risk
- Interventions
- Octaplex, Beriplex P/N (Kcentra)
- Drug
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 22
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 14 more
- Conditions
- Trauma Injury
- Interventions
- Prothrombin Complex Concentrate, Human, Placebo
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Hemophilia B
- Interventions
- Recombinant Coagulation Factor IX (BeneFIX)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Years to 65 Years · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Chicago, Illinois • New Brunswick, New Jersey + 1 more
- Conditions
- Hemophilia A With Inhibitors, Hemophilia B With Inhibitors
- Interventions
- Coagulation Factor VIIa (Recombinant)
- Biological
- Lead sponsor
- rEVO Biologics
- Industry
- Eligibility
- 12 Years to 75 Years · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Sacramento, California • Aurora, Colorado + 2 more
- Conditions
- Traumatic Injury
- Interventions
- BE1116, Placebo
- Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 15 Years and older
- Enrollment
- 1,366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 79 more
- Conditions
- Hemophilia B, Mucopolysaccharidosis I, Mucopolysaccharidosis II
- Interventions
- SB-318, SB-913, SB-FIX
- Biological
- Lead sponsor
- Sangamo Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 5
- States / cities
- Oakland, California • Chicago, Illinois • New York, New York + 2 more
- Conditions
- Hemophilia B
- Interventions
- rIX-FP
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- Up to 70 Years · Male only
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more
- Conditions
- Hemophilia B
- Interventions
- Not listed
- Lead sponsor
- Bloodworks
- Other
- Eligibility
- 16 Years and older · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Diego, California • New Orleans, Louisiana + 2 more
- Conditions
- Reversal of Coagulopathy
- Interventions
- Beriplex® P/N (Kcentra), Fresh frozen plasma
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 16
- States / cities
- Newark, Delaware • Lexington, Kentucky • Boston, Massachusetts + 13 more
- Conditions
- Hemophilia A
- Interventions
- Factor IX
- Drug
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 12 Years to 120 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Metairie, Louisiana • New Orleans, Louisiana
- Conditions
- Hemophilia B
- Interventions
- FLT180a
- Biological
- Lead sponsor
- University College, London
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee